Top Qs
Timeline
Chat
Perspective

Solangepras

Pharmaceutical compound From Wikipedia, the free encyclopedia

Solangepras
Remove ads

Solangepras (INNTooltip International Nonproprietary Name; developmental code name CVN-424), or solengepras (USANTooltip United States Adopted Name), is an inverse agonist of the orphan G protein-coupled receptor 6 (GPR6) which is under development for the treatment of Parkinson's disease.[1][2][3][4] It is a small molecule and is taken by mouth.[1][4] Solangepras produces hyperlocomotion and reverses haloperidol-induced catalepsy in rodents.[4] It is being developed by Cerevance.[1][2] As of October 2024, solangepras is in phase 3 clinical trials.[1][2]

Quick Facts Clinical data, Other names ...
Remove ads

References

Loading related searches...

Wikiwand - on

Seamless Wikipedia browsing. On steroids.

Remove ads